The CIP2A protein was first identified as a tumor associated antigen in hepatocellular carcinoma and gastric cancer patients by Soo Hoo et al. [7], who also suggested that CIP2A might also serve as an autoantigen in prostate cancer patients. This evidence concerns the gene CIP2A and prostate carcinoma.